Lipocine Inc.

Healthcare · Biotechnology · United States

Last price 1.44 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.87M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an...